EUVIMEDEUVIMED entdecken
Open Access

Type II kinase inhibitors that target Parkinson’s disease–associated LRRK2

Nicolai D Raig iD, Katherine J Surridge iD, Marta Sanz-Murillo iD, Verena Dederer iD, Andreas Krämer iD, Martin P Schwalm iD, Nicholas M Lattal, Lewis Elson iD, Deep Chatterjee, Sebastian Mathea iD, Thomas Hanke iD, Andres E Leschziner iD und 2 weitere

Science Advances · 06.06.2025 · 11 (23)

DOI: 10.1126/sciadv.adt2050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 06.06.2025. Verfasst von Nicolai D Raig und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmaceutical Chemistry, Goethe University, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Increased kinase activity of leucine-rich repeat kinase 2 (LRRK2) is associated with Parkinson’s disease (PD). Numerous LRRK2-selective type I kinase inhibitors have been developed, and some have entered clinical trials. Here, to our knowledge, we present the first type II kinase inhibitors that target LRRK2. Targeting the inactive conformation of LRRK2 is functionally distinct from targeting the active-like conformation using type I inhibitors. We designed these inhibitors with a combinatorial chemistry approach fusing selective LRRK2 type I and promiscuous type II inhibitors using iterative cycles of synthesis supported by structural biology and activity testing. Our lead compounds are selective and potent toward both LRRK2 and LRRK1, a close relative of LRRK2. Through cellular assays, cryo–electron microscopy structural analysis, and in vitro motility assays, we show that our inhibitors stabilize the open, inactive LRRK2 kinase conformation. These new conformation-specific compounds will be invaluable as tools to study LRRK2’s function and regulation and expand the potential therapeutic options for PD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Parkinson DiseaseCombinatorial Chemistry TechniquesDrug DesignProtein Structure, TertiaryHEK293 CellsHumansKinesins

Substanzen

Protein Kinase InhibitorsLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Kinesins

Autor:innen und Institutionen

  • Institute of Pharmaceutical Chemistry, Goethe University, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany.
  • Structural Genomics Consortium (SGC), Buchmann Institute for Life Sciences, Max-von-Laue-Str. 15, 60438 Frankfurt am Main, Germany.
  • Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD 20815, USA.
  • Department of Cell and Developmental Biology, School of Biological Sciences, University of California San Diego, La Jolla, CA 92093, USA.
  • Department of Cellular and Molecular Medicine, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
  • Department of Molecular Biology, School of Biological Sciences, University of California San Diego, La Jolla, CA 92093, USA.

ORCID-Profile: Nicolai D Raig, Katherine J Surridge, Marta Sanz-Murillo, Verena Dederer, Andreas Krämer, Martin P Schwalm, Lewis Elson, Sebastian Mathea, Thomas Hanke, Andres E Leschziner, Samara L Reck-Peterson, Stefan Knapp

Zitieren

APA

Raig, N. D., Surridge, K. J., Sanz-Murillo, M., Dederer, V., Krämer, A., Schwalm, M. P., Lattal, N. M., Elson, L., Chatterjee, D., Mathea, S., Hanke, T., Leschziner, A. E., Reck-Peterson, S. L., & Knapp, S. (2025). Type II kinase inhibitors that target Parkinson’s disease–associated LRRK2. Science Advances, 11(23). https://doi.org/10.1126/sciadv.adt2050

Vancouver

Raig ND, Surridge KJ, Sanz-Murillo M, Dederer V, Krämer A, Schwalm MP, et al. Type II kinase inhibitors that target Parkinson’s disease–associated LRRK2. Science Advances. 2025;11(23). doi:10.1126/sciadv.adt2050

BibTeX
@article{Raig2025,
  author = {Raig, Nicolai D and Surridge, Katherine J and Sanz-Murillo, Marta and Dederer, Verena and Krämer, Andreas and Schwalm, Martin P and Lattal, Nicholas M and Elson, Lewis and Chatterjee, Deep and Mathea, Sebastian and Hanke, Thomas and Leschziner, Andres E and Reck-Peterson, Samara L and Knapp, Stefan},
  title = {Type II kinase inhibitors that target Parkinson’s disease–associated LRRK2},
  journal = {Science Advances},
  year = {2025},
  volume = {11},
  number = {23},
  doi = {10.1126/sciadv.adt2050}
}
Kostenlos starten →